Growth Hormone Stack

The Growth Hormone Stack pairs two peptides that act on distinct receptor systems within the growth hormone axis. CJC-1295 (Mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH) — research indicates it may stimulate GH secretion by binding the GHRH receptor on pituitary somatotroph cells [PMID: 16352683]. Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist that studies suggest may trigger GH release through an entirely separate receptor pathway, producing a synergistic effect when combined with a GHRH analogue [PMID: 9758556].

What makes this combination particularly interesting in endocrinology research is the dual-receptor mechanism: CJC-1295 amplifies the amplitude of natural GH pulses via the GHRH pathway, while Ipamorelin simultaneously activates the ghrelin axis. Studies suggest this combination may produce substantially greater GH release than either peptide alone, while Ipamorelin's high receptor selectivity minimizes the cortisol and prolactin elevations associated with older growth hormone releasing peptides [PMID: 9758556].

Both compounds remain classified as research peptides. Evidence is drawn primarily from preclinical models and limited human pharmacokinetic studies. This page presents the published scientific literature as a resource for researchers — not as guidance for human use, treatment, or diagnosis.

CJC-1295 (also known as Modified GRF 1-29) is a truncated and stabilized analogue of endogenous GHRH. Research suggests it may bind to the GHRH receptor on pituitary somatotrophs, stimulating pulsatile secretion of growth hormone and downstream IGF-1 production [PMID: 16352683]. Unlike the original CJC-1295 with Drug Affinity Complex (DAC), the no-DAC version has a shorter half-life that more closely mimics the natural pulsatile pattern of GHRH signaling — a feature researchers consider important for preserving physiological GH release rhythms.

Ipamorelin contributes a mechanistically distinct and complementary stimulus. As a selective GHSR-1a agonist, it activates the ghrelin receptor pathway to trigger GH secretion independently of the GHRH receptor [PMID: 9758556]. This dual-pathway activation is the core rationale for the combination: the two peptides engage the GH axis at different molecular entry points, which studies suggest may produce a synergistic GH pulse significantly greater than either compound could generate individually.

A particularly important property of Ipamorelin is its selectivity profile. Earlier GHRPs — particularly GHRP-2 and GHRP-6 — were noted to stimulate cortisol and prolactin release alongside GH, complicating research protocols. Studies suggest Ipamorelin produces minimal cortisol or prolactin elevation at standard doses [PMID: 9758556], making it the preferred ghrelin receptor agonist for research combinations where GH-specific effects are the focus.

Taken together, CJC-1295 and Ipamorelin represent what researchers describe as a GHRH + GHRP synergy model: GHRH analogue amplifies GH pulse amplitude via pituitary sensitization, while the GHRP activates a parallel ghrelin-axis stimulus. No direct human clinical trial has evaluated this combination specifically, but the mechanistic rationale is grounded in well-established endocrinology of the GH axis.

Both peptides in this stack are administered via subcutaneous injection, and their timing relative to each other is an active area of discussion in the research literature. The prevailing hypothesis is that co-administration — injecting both peptides simultaneously or within a short window — may maximize the synergistic GH pulse by ensuring both receptor systems are activated concurrently. Studies on the natural GH axis suggest that GHRH and ghrelin signals are most potent when delivered together [PMID: 9758556].

Research protocols commonly reference administering Ipamorelin at 200–300 mcg per injection, 1–3 times daily, typically timed around sleep onset (to align with the natural nocturnal GH surge) and/or fasted morning and pre-exercise windows. CJC-1295 no-DAC is typically referenced at doses in the 100–200 mcg range per injection, co-administered with Ipamorelin. The no-DAC formulation's shorter half-life of approximately 30 minutes is considered more compatible with pulsatile administration than the DAC version's multi-day half-life.

Research protocols with this combination typically run 8–12 weeks, reflecting the time required to observe downstream IGF-1 and body composition endpoints in preclinical models. Because GH secretagogues interact with the endocrine axis, researchers consider careful protocol design — including washout periods and baseline measurement — essential for interpreting results. As with all research peptides, no established human safety profile exists for this combination, and all available dosing information is derived from preclinical studies and uncontrolled anecdotal sources.